Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
AIIMS New Delhi now provides free Therapeutic Drug Monitoring for epilepsy patients, eliminating costly private lab fees. Learn how this improves treatment and saves money.
AIIMS New Delhi now provides free Therapeutic Drug Monitoring for epilepsy patients, saving costs up to ₹1,880 per test. This move aims to improve treatment outcomes and adherence. Read more.
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Discover the top 5 wellness trends for 2026 in India, from AI-designed workouts and Hyrox races to smarter gear and affordable weight-loss drugs. Stay ahead in your fitness journey!
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Tamil Nadu CM M K Stalin demands unified action from Centre & state to curb drug menace. He also urges the art industry to responsibly highlight drug evils. Read more.
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Aurobindo Pharma strengthens its domestic formulations market with a ₹325 crore acquisition of Khandelwal Laboratories' non-oncology business. The deal includes 23 established brands and boosts presence in pain & anti-infective segments. Read more.
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
The Indian government has prohibited the manufacture and sale of high-dose Nimesulide painkillers, citing health risks. Safer alternatives are available. Read the full details and implications.
Explore how 2025's weight-loss drug boom in India shifted focus from fitness to thinness, raising concerns about medicalisation, side effects, and societal pressure. Read the full analysis.
Explore how 2025 cemented wellness into daily Indian life. Discover trends like social fitness, hybrid athletes, padel, weight-loss drugs, and open perimenopause talks. Dive in!
A Bengaluru software engineer was arrested for allegedly manufacturing synthetic drugs like MDMA in a makeshift home laboratory. Police seized drugs worth lakhs and equipment. Read the shocking details.
Rajkumar Bafna, Finance President of Akums Drugs, resigns citing severe Delhi pollution as the primary reason. Read the full story on this corporate exit driven by environmental concerns.
A senior pharmaceutical executive resigns, citing Delhi's severe air pollution as the primary reason. This drastic move highlights the city's escalating public health emergency. Read more about the human cost of India's air quality crisis.
Drugs Control Administration officials raided an unlicensed clinic in Karimnagar, seizing illegal steroids and antibiotics. The crackdown highlights the public health risks of unauthorized drug sales. Read more.
Rajkumar Bafna, President of Finance at Akums Drugs, resigns citing Delhi's toxic air. His case highlights a growing trend of professionals leaving the capital for health reasons. Read the full story.
As GLP-1 drugs like Ozempic launched in India, experts warn they are not a magic fix. Sustainable metabolic health requires diet, exercise, and stress management. Learn why.
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Women share harrowing experiences of stopping anti-obesity drugs like Wegovy. Experts warn 60-80% weight returns without a plan. Learn about the side effects and new drugs in India.